The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
- Sponsor
- Hvidovre University Hospital
- Study ID
- NCT02584582
- Phase
- PHASE2/PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide — DRUG
- Exenatide — DRUG
- Liquid meal test — PROCEDURE
- No drug (Baseline day) — OTHER
Study Details
Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent of the gastric emptying rate.
Key Dates
- Start date
- Jul 31, 2015
- Status verified
- Oct 2015
- Primary completion
- Nov 30, 2015
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Liraglutide + Liquid meal testLiraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)
- Experimental: Exenatide + Liquid meal testExenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
- Other: Baseline + Liquid meal testBaseline day with no additional medication
Primary Outcome Measure
Glucagon concentration (postprandial) [ Time Frame: 4 hours ]
Related Studies
- Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1EARLY_PHASE1 · Recruiting · Augusta University · Augusta, Georgia
- General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care DeliveryRecruiting · Sanford Health · Bemidji, Minnesota
- The T1D Exchange RegistryRecruiting · T1D Exchange, United States · Boston, Massachusetts
- Combined Antibody Screening for Celiac and Diabetes EvaluationEnrolling By Invitation · Pacific Northwest Research Institute · Seattle, Washington